Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Organon & Co. Common Stock — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $103.46 (market cap $29.10B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is far larger — about 8.1× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 126 Days and Organon & Co. Common Stock for 0 Days on average.
| LQD | OGN | |
|---|---|---|
Market Cap | $29.10B | $3.61B |
Volume | 33,185,388 | 1,808,049 |
Sector | Fixed Income | Health |
52-Week High | $112.91 | $13.81 |
52-Week Low | $101.83 | $5.70 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | — | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $102.55, showing minimal daily movement with a slight decline of -0.03%. The ETF faces bearish technical signals across multiple indicators while maintaining regular dividend distributions. Recent news highlights significant short interest growth of 53.1% in September 2026 and unusual options activity, reflecting heightened market uncertainty amid rising bond yields and geopolitical tensions affecting corporate debt markets.
The investment-grade corporate bond ETF faces headwinds from rising Treasury yields and increased borrowing costs for corporations. While the 4.8% yield provides income appeal, the bearish technical outlook and growing short interest suggest near-term pressure. Key risks include further Fed rate hikes and economic slowdown impacting corporate credit quality.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
